Published in N Engl J Med on January 08, 2004
Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am J Pathol (2005) 5.88
Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med (2005) 4.25
The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol (2007) 3.33
Strategies for treating idiopathic pulmonary fibrosis. Nat Rev Drug Discov (2010) 3.20
Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med (2013) 2.86
Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc (2006) 2.40
Idiopathic pulmonary fibrosis. Orphanet J Rare Dis (2008) 2.34
Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. Am J Respir Crit Care Med (2005) 2.29
Regulation of pulmonary fibrosis by chemokine receptor CXCR3. J Clin Invest (2004) 2.10
Early interstitial lung disease in familial pulmonary fibrosis. Am J Respir Crit Care Med (2007) 1.91
Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS One (2007) 1.88
Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2006) 1.80
The elusive goal of therapy for usual interstitial pneumonia. N Engl J Med (2004) 1.70
Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review. Thorax (2005) 1.64
Oxidative stress and glutathione in TGF-beta-mediated fibrogenesis. Free Radic Biol Med (2009) 1.61
Study design implications of death and hospitalization as end points in idiopathic pulmonary fibrosis. Chest (2014) 1.51
Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest (2009) 1.50
Natural killer cells in infection and inflammation of the lung. Immunology (2009) 1.46
British Thoracic Society Study on cryptogenic fibrosing alveolitis: Response to treatment and survival. Thorax (2006) 1.39
Molecular and cellular mechanisms of pulmonary fibrosis. Fibrogenesis Tissue Repair (2012) 1.37
Regional chest wall volumes during exercise in chronic obstructive pulmonary disease. Thorax (2004) 1.36
Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial. Respir Res (2009) 1.34
Predicting pulmonary fibrosis disease course from past trends in pulmonary function. Chest (2014) 1.25
Novel therapeutic approaches for pulmonary fibrosis. Br J Pharmacol (2011) 1.24
In vivo IL-10 gene delivery attenuates bleomycin induced pulmonary fibrosis by inhibiting the production and activation of TGF-beta in the lung. Thorax (2006) 1.24
Idiopathic pulmonary fibrosis: current understanding of the pathogenesis and the status of treatment. CMAJ (2004) 1.21
Mesenchymal cell survival in airway and interstitial pulmonary fibrosis. Fibrogenesis Tissue Repair (2010) 1.17
TNF-alpha sensitizes normal and fibrotic human lung fibroblasts to Fas-induced apoptosis. Am J Respir Cell Mol Biol (2005) 1.17
Determinants of initiation and progression of idiopathic pulmonary fibrosis. Respirology (2009) 1.16
Development and validity testing of an IPF-specific version of the St George's Respiratory Questionnaire. Thorax (2010) 1.14
Natural killer T (NKT) cells attenuate bleomycin-induced pulmonary fibrosis by producing interferon-gamma. Am J Pathol (2005) 1.08
Cytokine mediated tissue fibrosis. Biochim Biophys Acta (2012) 1.06
The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial. Respir Res (2011) 1.06
Therapeutic value of small molecule inhibitor to plasminogen activator inhibitor-1 for lung fibrosis. Am J Respir Cell Mol Biol (2012) 1.06
The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis. Respir Med (2012) 1.04
Toll-like receptors, Notch ligands, and cytokines drive the chronicity of lung inflammation. Proc Am Thorac Soc (2007) 1.03
New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis. Drugs (2011) 1.03
New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses. Am J Respir Crit Care Med (2014) 1.02
Clinical trials: discerning hype from substance. Ann Intern Med (2010) 1.02
Escape from the matrix: multiple mechanisms for fibroblast activation in pulmonary fibrosis. Proc Am Thorac Soc (2008) 0.99
Treatment of idiopathic pulmonary fibrosis with losartan: a pilot project. Lung (2012) 0.98
Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians. Respir Med (2007) 0.98
Increased incidence of autoimmune markers in patients with combined pulmonary fibrosis and emphysema. BMC Pulm Med (2013) 0.96
The fibroproliferative response in acute respiratory distress syndrome: mechanisms and clinical significance. Eur Respir J (2013) 0.95
Pathogenesis, current treatments and future directions for idiopathic pulmonary fibrosis. Curr Opin Pharmacol (2013) 0.94
Current and novel drug therapies for idiopathic pulmonary fibrosis. Drug Des Devel Ther (2012) 0.93
Update on diagnosis and treatment of idiopathic pulmonary fibrosis. J Bras Pneumol (2015) 0.92
Pulmonary vaccination as a novel treatment for lung fibrosis. PLoS One (2012) 0.91
Update on therapeutic management of idiopathic pulmonary fibrosis. Ther Clin Risk Manag (2015) 0.91
Overexpression of the transcription factor GATA-3 enhances the development of pulmonary fibrosis. Am J Pathol (2006) 0.90
Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy. Treat Respir Med (2006) 0.90
The role of long-term doxycycline in patients of idiopathic pulmonaryfibrosis: The results of an open prospective trial. Lung India (2009) 0.90
Fibrocytes and the pathogenesis of diffuse parenchymal lung disease. Fibrogenesis Tissue Repair (2012) 0.89
Clinical use of biomarkers of survival in pulmonary fibrosis. Respir Res (2010) 0.89
Innate immunity dictates cytokine polarization relevant to the development of pulmonary fibrosis. J Clin Invest (2004) 0.88
Patient-reported outcomes in idiopathic pulmonary fibrosis research. Chest (2012) 0.88
The psychometric properties of the St George's Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review. Health Qual Life Outcomes (2014) 0.87
Thiopurine S- methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis. Lung (2010) 0.87
The treatment of idiopathic pulmonary fibrosis. F1000Prime Rep (2014) 0.86
Idiopathic Pulmonary Fibrosis: Gender-Age-Physiology Index Stage for Predicting Future Lung Function Decline. Chest (2016) 0.86
Recommendations on treatment for IPF. Respir Res (2013) 0.86
The current position of surgical lung biopsy in the diagnosis of idiopathic pulmonary fibrosis. Respir Res (2013) 0.85
Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate. Thorax (2007) 0.85
Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management. Trans Am Clin Climatol Assoc (2004) 0.84
Pirfenidone treatment of idiopathic pulmonary fibrosis. Ther Clin Risk Manag (2011) 0.83
Interferon-gamma-mediated inhibition of serum response factor-dependent smooth muscle-specific gene expression. J Biol Chem (2010) 0.82
Decreased apoptotic rate of alveolar macrophages of patients with idiopathic pulmonary fibrosis. Pulm Med (2012) 0.82
An alternative therapy for idiopathic pulmonary fibrosis by doxycycline through matrix metalloproteinase inhibition. Lung India (2011) 0.81
A network model of correlated growth of tissue stiffening in pulmonary fibrosis. New J Phys (2014) 0.81
Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future. Ann Med (2015) 0.81
A critical assessment of treatment options for idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis (2005) 0.81
Adjuvant interferon gamma in patients with pulmonary atypical Mycobacteriosis: a randomized, double-blind, placebo-controlled study. BMC Infect Dis (2008) 0.81
The efficiency of a urotensin II antagonist in an experimental lung fibrosis model. Inflammation (2012) 0.80
Health-related quality of life and 6 min walk distance in patients with idiopathic pulmonary fibrosis. Can Respir J (2011) 0.80
Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1). Eur Respir J (2009) 0.80
Vaccinia vaccine-based immunotherapy arrests and reverses established pulmonary fibrosis. JCI Insight (2016) 0.80
Idiopathic Pulmonary Fibrosis: Adaptive Multiple Features Method Fibrosis Association with Outcomes. Am J Respir Crit Care Med (2016) 0.79
Effect of treatment guidelines on the initial management of idiopathic pulmonary fibrosis. Br J Clin Pharmacol (2010) 0.79
Quantitative assessment of lung ventilation and microstructure in an animal model of idiopathic pulmonary fibrosis using hyperpolarized gas MRI. Acad Radiol (2010) 0.79
Clinical predictors of survival in idiopathic pulmonary fibrosis. Tuberc Respir Dis (Seoul) (2012) 0.79
Clinical trials and tribulations--lessons from pulmonary fibrosis. QJM (2012) 0.78
Pulmonary hypertension in patients with idiopathic pulmonary fibrosis - the predictive value of exercise capacity and gas exchange efficiency. PLoS One (2013) 0.78
The diagnosis and treatment of idiopathic pulmonary fibrosis. Dtsch Arztebl Int (2013) 0.78
Idiopathic pulmonary fibrosis: new insights on functional characteristics at diagnosis. Can Respir J (2014) 0.78
Enhanced protection from fibrosis and inflammation in the combined absence of IL-13 and IFN-γ. J Pathol (2016) 0.77
Do we need exercise tests to detect gas exchange impairment in fibrotic idiopathic interstitial pneumonias? Pulm Med (2012) 0.77
Advances in the management of idiopathic pulmonary fibrosis. F1000 Med Rep (2010) 0.77
Madecassoside ameliorates bleomycin-induced pulmonary fibrosis in mice through promoting the generation of hepatocyte growth factor via PPAR-γ in colon. Br J Pharmacol (2016) 0.77
RAGE and TGF-β1 Cross-Talk Regulate Extracellular Matrix Turnover and Cytokine Synthesis in AGEs Exposed Fibroblast Cells. PLoS One (2016) 0.77
Idiopathic pulmonary fibrosis is associated with circulating antiepithelial antibodies. Lung (2012) 0.76
IL-10: Another therapeutic target in idiopathic pulmonary fibrosis? Thorax (2006) 0.76
Interferon gamma-1b for pulmonary fibrosis. N Engl J Med (2004) 0.75
Interferon gamma-1b for pulmonary fibrosis. N Engl J Med (2004) 0.75
Interferon gamma-1b for pulmonary fibrosis. N Engl J Med (2004) 0.75
Idiopathic pulmonary fibrosis in Saudi Arabia: Demographic, clinical, and survival data from two tertiary care hospitals. Ann Thorac Med (2014) 0.75
Aerobic Exercise Attenuated Bleomycin-Induced Lung Fibrosis in Th2-Dominant Mice. PLoS One (2016) 0.75
Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy. Core Evid (2016) 0.75
The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis. Respir Med (2015) 0.75
Interferon gamma-1b for pulmonary fibrosis. N Engl J Med (2004) 0.75
Clinical trials of investigational agents for IPF: a review of a Cochrane report. Respir Res (2013) 0.75
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 22.39
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med (2014) 10.62
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med (2014) 9.40
Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med (2005) 8.49
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med (2013) 6.82
Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med (2011) 6.74
Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 6.71
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med (2012) 6.51
A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med (2011) 6.40
Standardizing global gene expression analysis between laboratories and across platforms. Nat Methods (2005) 6.23
Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med (2002) 6.00
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet (2011) 5.94
Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2006) 5.86
An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med (2012) 5.37
Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med (2012) 5.33
Clinical decisions. American Board of Internal Medicine maintenance of certification program. N Engl J Med (2010) 4.85
Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron (2005) 4.78
Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am J Respir Crit Care Med (2002) 4.66
Toll-like receptors in the pathogenesis of human disease. Nat Immunol (2004) 4.40
Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med (2005) 4.25
The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med (2005) 4.25
The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med (2005) 4.15
Resolution of lung inflammation by CD44. Science (2002) 4.09
Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med (2002) 4.00
Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med (2008) 3.97
Signaling properties of hyaluronan receptors. J Biol Chem (2001) 3.95
Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2003) 3.89
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med (2011) 3.85
Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc Natl Acad Sci U S A (2011) 3.82
Hyaluronan in tissue injury and repair. Annu Rev Cell Dev Biol (2007) 3.62
Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. Chest (2006) 3.59
BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 3.49
Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2010) 3.37
In utero supplementation with methyl donors enhances allergic airway disease in mice. J Clin Invest (2008) 3.35
Gene expression profiling of familial and sporadic interstitial pneumonia. Am J Respir Crit Care Med (2006) 3.32
Genetic analysis of complex traits in the emerging Collaborative Cross. Genome Res (2011) 3.25
BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2011) 3.23
Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet (2009) 3.21
Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet (2013) 3.17
Protection from experimental asthma by an endogenous bronchodilator. Science (2005) 3.17
Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med (2010) 3.05
Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med (2003) 3.00
Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med (2004) 2.97
Type 2 alveolar cells are stem cells in adult lung. J Clin Invest (2013) 2.93
6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J (2013) 2.92
Early growth response gene 1-mediated apoptosis is essential for transforming growth factor beta1-induced pulmonary fibrosis. J Exp Med (2004) 2.84
Hyaluronan as an immune regulator in human diseases. Physiol Rev (2011) 2.74
Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol (2013) 2.74
Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med (2007) 2.69
Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med (2007) 2.66
Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med (2008) 2.65
Sarcoidosis-related mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med (2011) 2.62
Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med (2011) 2.62
Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J (2012) 2.57
Allergen-induced airway disease is mouse strain dependent. Am J Physiol Lung Cell Mol Physiol (2003) 2.56
Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2011) 2.54
A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med (2012) 2.54
Connective tissue disease-associated interstitial lung disease: a call for clarification. Chest (2010) 2.51
Human pulmonary chimerism after hematopoietic stem cell transplantation. Am J Respir Crit Care Med (2003) 2.50
The role of innate immunity in acute allograft rejection after lung transplantation. Am J Respir Crit Care Med (2003) 2.44
The role of Toll-like receptor 4 in environmental airway injury in mice. Am J Respir Crit Care Med (2004) 2.43
Role of surfactant proteins A, D, and C1q in the clearance of apoptotic cells in vivo and in vitro: calreticulin and CD91 as a common collectin receptor complex. J Immunol (2002) 2.43
Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med (2004) 2.42
Case-control study of shigellosis in San Francisco: the role of sexual transmission and HIV infection. Clin Infect Dis (2006) 2.41
Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc (2006) 2.40
Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med (2010) 2.40
Fibroblast foci are not discrete sites of lung injury or repair: the fibroblast reticulum. Am J Respir Crit Care Med (2006) 2.34
Idiopathic pulmonary fibrosis. Orphanet J Rare Dis (2008) 2.34
Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2011) 2.32
MUC5B promoter polymorphism and interstitial lung abnormalities. N Engl J Med (2013) 2.31
Cutting edge: TLR4 deficiency confers susceptibility to lethal oxidant lung injury. J Immunol (2005) 2.30
Exposures to the Kuwait oil fires and their association with asthma and bronchitis among gulf war veterans. Environ Health Perspect (2002) 2.24